The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Trial in progress: A phase I trial of dual EZH 1/2 inhibitor valemetostat tosylate (DS-3201b) in pediatric, adolescent, and young adult patients with malignant solid tumors.
 
Ayumu Arakawa
Research Funding - Chugai Pharma (Inst)
Travel, Accommodations, Expenses - Amgen
 
Hitoshi Ozawa
No Relationships to Disclose
 
Akihiro Hirakawa
No Relationships to Disclose
 
Ryo Sadachi
No Relationships to Disclose
 
Yukari Hoshina
No Relationships to Disclose
 
Sawako Tomatsuri
No Relationships to Disclose
 
Yoshimasa Saito
No Relationships to Disclose
 
Reiko Makihara Ando
No Relationships to Disclose
 
Keita Terashima
Research Funding - AstraZeneca (Inst); Novartis (Inst)
 
Kenichi Nakamura
Honoraria - Chugai Pharma; IQvia; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); Boehringer Ingelheim Seiyaku (Inst); Bristol-Myers Squibb Japan (Inst); Chugai/Roche (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Chitose Ogawa
Honoraria - Chugai Pharma; Ohara Pharmaceutical
Research Funding - Ono Pharmaceutical (Inst)